BCL9 and ductal breast carcinoma in situ: Among the MMPs tested, BCL9-KD significantly decreased baseline MMP16 mRNA levels in DCIS.COM cells as well as BCL9-KD cells treated with 500 ng/ml Wnt3A (Supplementary Fig. 7b).